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Epidermal calmodulin (CaM) has been reported to be el-
evated in psoriasis and to decrease following clea rance of 
psoriasis with treatment. We set out to inves tiga te whether 
any of the principle drugs used in the trea tment of psoriasis 
had inherent CaM antagonist activity. Utilizing a CaM-
activated phosphodiesterase we have demonstrated that even 
at very high concentrations, the sys temic drugs etretinate, 
methotrexate, and 8-methoxypsoralen, and the topical agents 
L evels of the intracellular calcium binding protein cal-modulin (CaM) have been shown to be elevated in both lesionQl [1-5] and nonlesional [2-5] psoriatic epidermis. CaM regulates a w ide range of intracellular processes , several of which have been reported to be altered in 
psorias is; thus CaM activates a number of enzymes including 
cycl ic nucleotide phosphodiesterase, phospholipase A2, and or-
nithine decarboxylase. whose levels and those of their products 
are known to be abnorm al in pso rias is [6- 8]. In addition, the 
epidermis is hyperproliferative in psorias is, and there is a consid-
erable body of evidence that CaM is essent ial for the regulation 
of cell di vision [9]. An alteration in the regulation of CaM activity 
in the psoria tic epidermis would therefore help to explain a num-
ber of seemingly unrelated abnorm alities. 
We have recentl y shown that a successful res ponse to treatment 
in psorias is, by a variety of established treatment regimens, is 
associated with a decrease in epiderm al CaM activity to within 
the normal range for control volunteers with little change in those 
individuals where CaM levels were already low [10]. This latter 
study led us to consider whether any of the established topical 
and systemic methods of treatment fo r pso rias is (for some of 
which the mode of action in psoriasis is not clearly established) 
had any inherent CaM antagonist ac tivity. Acco rdin gly we have 
investigated the ability of 3 topical agents, dithranol, hydrocor-
tisone, and crude coal tar, and 3 systemic dru gs , etretinate, metho-
Manuscri pt received October 8, 1985; accepted for publica tion February 
7, 1986. 
T his work has been supported by the Psori as is Association of Great 
Britain and the Wellcome T rust. 
* A prelim inary account of th is work was presented at the Annual 
Meeting of the British Society for In ves tigative Dermatology . Oxford, 
September 1985 (B r J Dermatol 11 3:794-795, 1985). 
Reprint req ues ts to: Dr. William F. G. T ucker. T he University of 
Sheffield. Academic Division of Medicine. Royal Hallamshire Hospital. 
Sheffield S10 2J F, England. 
Abbreviations: 
Ca M: calmodulin 
W7: N-(6-aminohexyl)-5-chloro-1-naphthalene sulfona mide 
hydrocortisone and crude coal tar showed minimal C aM 
inhibitory activity. Dithranol (anthralin), however, whether 
freshly prepared or oxidized, produced substantial inhibi-
tion of CaM activity and was demonstrated to be a potent 
competitive antagonist of CaM, suggesting another pos-
sible therapeutic mode of action of dithranol in psoriasis . 
J Invest D ermatol 87:232-235, 1986 
trexate, and 8-methoxypsoralen to inhibit the CaM activation of 
a CaM-sensitive enzyme, beef heart phosphodiesterase. 
MATERIALS AND METHODS 
Assessment of the Effect of Drugs on Calmodulin 
Activity Calmodulin ac tivi ty was measured based on its acti-
vation of a CaM-dependent beef heart phos phodiesterase (Boeh-
ringer Mannheim , London) as described previously [11] . Assays 
contained in a fin al reaction mixture of 400 J.LI, 40 mM Tris-HCI, 
pH 7.0 at 37°C, 4 mM 2-mcrca ptoethanol, 5 mM M gClz, 
3H-labeled cyclic AMP (2 x 105 cpmltube) (Amersham Inter-
national Limited, Bucks, U .K .), 100 J.LM cyclic AMP (Boehringer 
Mannheim, London), 25 J.LM C aCh, and pure CaM and drugs as 
required . Pure CaM was prepared from pig brain by the method 
of Kakiuchi et al [12] . 
Incubations were for 15 min at 37°C. For assess ment o f the 
potential inhibitory cffects of the drugs, assays contained suffi-
cient CaM (12.5 ng/400 J.Ll incubation) to produce 60- 80% o f the 
maximum response to CaM . The antipsoriatic drugs tested were 
etretinate (Roche Products Limited, Welwyn Garden City, Herts, 
U . K.), methotrexate (Lederle Laboratories Division , Cyanam id 
of Great Britain Ltd .), 8-methoxypsoralen (supplied as a gift fro m 
U pj ohn Ltd ., Fleming Way, Crawley, West Sussex), crude coal 
tar (Thornton & Ross, Linthwaite Laboratories, Huddersfield), 
dithranol (Staveley C hemi cals Ltd. , Staveley Works, Chester-
fi eld , Derbyshire), and hydrocortisone acetate (The Boots C om-
pany PLC, N ottingham). Two oxidative products of dithranol, 
1,8-dihydroxyanthraquinone and dithranol dehydrodimer, were 
also kindl y supplied by Dr. M . Whitefi eld of Dermal Laboratorie 
Ltd ., Hitchin , Hertfordshire. The CaM antagonist N-(6-amino-
hexyl)-5-chloro-1-naphthalene sulphonamide (W7) (supplied as a 
gift from Dr. M . Blackburn , Department of C hemistry, Sheffield 
University) was also used for comparative purposes in this study. 
For etretinate and 8-methoxypsoralen it w as necessary to solu-
bilize these dru gs first in DMSO, and 2% DMSO was accordingly 
added to all incubations with these drugs . C rude coal tar and 
dithranol were solubilized first in ethanol and 2. 5% ethanol wa 
present throughout all incubations with these drugs. (DMSO at 
2% and ethanol at 2. 5% signifi cantly lowered both CaM-inde-
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pendent and CaM-dependent phosphodiesterase activity. T he re-
sponse of the enzyme to CaM was not itself affec ted .) 
Each drug w as tested over a wide range of concentrations (all 
were tested up to 2.5 X lO - J g/liter and higher where so lubility 
permitted) in o rd er to include those concentrations li kely to be 
achieved systemically o r loca ll y in clini cal usage . 
Incubations w ere performed in triplica te and each experiment 
was repeated on a minimum of 3 occasions. 
Student's [-test w as used to eva luate the statist ical significance 
of the effects of the dru gs on CaM act ivity. 
RESULTS 
The m ajority of the anti psoriatic drugs studied showed minimal 
CaM inhibitory activity even at very hig h concentra tions (see Fig 
1) . Thus , methotrexate at 2.5 x 1O - J gil iter, etretinate at 2.5 X 
10- 3 g/liter, 8-methoxypsoralen at 2.5 x 10 - 1 g/liter, hydro-
cortisone at 2 .5 X 10- 1 g/Jiter , and crudc coal tar at 2.5 X 10- 2 
g/iiter inhibited CaM-dependent activation of beef heart phos-
pliodies terase by 20% or less. (Although 8-methoxypsoralen had 
no CaM antagonist properties in its own ri ght, we sho uld point 
ou t that it is norma ll y given clinica ll y in co mbin ation w ith UV A 
irradiation) . SolLibility problems with etretinatc and coal tar pre-
vented testing of thcse subst<1 nces a t an y hig her concentrations. 
The deg ree of inhibition achieved at th ese concentrations varied 
from experiment to experiment and , overall , did not achieve 
statistical signifIcance (p > 0.05). Dithrano l, however , signifi-
cantly inhibited CaM activity (Fig 1) with 50% inhibition of 
CaM-dependcnt phosphodiesterase activ ity occurring at 5.5 ± 
0.04 x lO- J g/ liter (± SEM , n = 3 experiments), equivalent to 
24 Ji-M (p < 0.005). In co mparison, in these experiments the CaM 
antagonist W7 produced 50% inhibition (ICsu) at 1 X 10- 2 g/ liter, 
equivalent to 29 Ji-M . 
We examined the inhibitory effect of dithrano l (1 ,8-dih ydroxy-
9- anthron e) in g reater detail as shown in Figs 2 and 3. Dithranol 
exposed to air and su nlight quite quickl y becomes discolored as 
it is oxidized to danthron (1,8-dihydroxyanthraquinone) and 
dianthrone, a dithranol dehydrodimer (1,8, 1 ', 8 '-tctrahydroxy-
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Figure 1. The effects of methotrexate (1) . etretinate (2). 8-methoxy-
psoralen (3). dithranol (4), crude coal tar (.5), hydrocortisone (6) , and the 
CaM antagonist N-(6-aminohexyl)-5-chloro- l-naphthalene sulfonamide 
(W7) (7) on CaM-activated phosphodiesterase. The results shown are of 
single representative experiments for each drug (repeated on at least 2 
other occasions). Data from separate experiments are combined by des-
ignating the increase in phosphodiesterase activity due to CaM (CaM-
independcnt enzyme activity of approximately 20% is subtracted) as \ 00%. 
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Figure 2. T he effect of dithr~nol on the abi lity of Ca M to stimulate beef 
heart Ca M-dependent phosphodiesterase activity. Incubations contained 
Ca M alone (closed circle) or CaM plus 2.5 x 10 - 2 g/ liter freshly made up 
dithranol (opei l trit/ lIs le) or Ca M plus 2.5 x 10 - 2 glliter dithranol allowed 
to stand in the sun fo r approximately 3 weeks (opell circle). 
10, 10' -bi-9[1 OHJ-anth rone). We cxamined th e CaM anragonist 
pro penies of fres hly prepared dithranol and of oxidized dithrailOl 
solutions and found bo th inhibited CaM acti vity to a simi lar 
extent, w ith the so le diffcrence being that fres h dithrano l also 
inhibited basal phosphodies terasc ac tivity which is Ca M-indc-
pendent (Fig 2). Oxidized dithranol solutions did not affect basal 
enzy m e act ivity even up to 2.5 x 10 - 2 g/liter. . 
We confirmed thc CaM- antagonist properties of ox idized dith-
ranol solutio ns by examining pure prepara tions o f the 2 most 
C0111mon oxidation products of dithranol-danthron and the dith-
rano l dchydrodimer. The form er was equipotent w ith dithranol 
in inhibiting CaM activity; the latter appeared to be sli ghtly less 
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Figure 3. Kinetic analysis of the dithranol-indu ced inhibition of acti-
vation of beef heart phosphodiesterase by pure Ca M. Phosphodiesterase 
activity was measured in the presence of 0, 2.5 x 10 - 4 g/l iter, and 
2.5 x 'lO - J g/liter dithranol over a range of Ca M concentrations. Data 
arc plolted as 1 IV vs 1/CaM . where V is nmol cyclic AMP hydrolyzed 
min - I m U phosphodiesterase and Ca M conccntration is ng of Ca M per 
400 J.LI incubation. Each poillf represents the mean of triplica te determi-
nations. The in crease in slope due to 2.5 X IO - J gi l iter dithranol was 
used to calculate Ki using the relationship that this increase represents 
1 + IIIIK i . 
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potcnt , although thc ex tremel y low water sol ubility of thc dc-
hyd rod imcr made working with this form ex trcm cly diffi cult . 
Increasing conccntrations o f CaM reduced the inhibition produccd 
by dithrano l whereas increasing conccntrations of calcium (up to 
1 mM) (on w hi ch the enzy m e is also dependent) did no t affcct 
the inhibitio n . Kineti c anal ys is of th e inhibition using a double-
reciproca l Lincweaver-Burk plo t (Fig 3) showcd th at the V""" 
(y axis intercept) va lues for thc Ca M-stimulated enzyme act ivity 
in the absence of drug and in thc presence of 2.5 X 10 - 4 and 
2.5 x 10 - 3 g/liter dithranol were the sa m e and that th e apparent 
K", (s lope = K", /VIlI :o x ) of CaM decreased w ith increasing con-
centratio ns of dithrano l. This is consistent w ith dithranol acting 
as a co mpetiti ve inhibitor of Ca M. The increase in slope in the 
double-reciprocal plot produ ced by 2.5 X 10 - 3 g/ liter dithranol 
was used to calculate the inhibito r constant K; [1 3]. using the 
relatio nship that this increase in slope is equiva lent to 1 + [1]1 K ; 
[1 01. This ga ve an inhibitor constant for dithranol of2.5 x 10 - 3 
g/ liter. 
D ISC USSION 
We have previously repo rted that bo th biologica lly active and 
radio immunoassaya blc levels of CaM are increased 2- to 3-fold 
in the psoriatic plaque, and are also slightl y increased in th e un-
in volved epidermis in psoriasis [2,4]. O ur finding th at there is an 
intrinsi c elevation in the nonlesional epidermis has now been 
confirmed b y 2 othcr groups, Fairley ct al [3] and Mizumoto et 
al [5 j . T hc 2- to 3-fo ld elevation in CaM seen by these workers 
and by us in the psori ati c pl aq ue is o f a similar order to that 
reportcd in virally transformed cell s [14]. and to the CaM levels 
we h~ve observed in va rio us neoplas ti c tissues. Cellular hyper-
proliferation alo ne, however, does no t seem to ex plain this ele-
var io n, since we have found no signifi cant increase in CaM levcls 
in normal control epidermis induced to proliferate by plastic tape 
strippin g, or in lymphocytes stim.ulated to divide by phy tohem-
agglutinin [4 1. 
Whether or not increased Ca M activity in psoriatic epidermis 
is onc of the ini tiating biochemical changes in psorias is, we have 
shown that clini cal improvem ent in pso riasis is associated with 
decreased CaM activity in the lesional epidermis [1 0] (CaM ac-
tivity in the uninvolved epidermis rem ained slightly elevated) . 
The possibility that some o f the current psoriasis trea tmen t reg-
imens might affect CaM acti vity directly seem ed worth y of ex-
am in ation , particul arl y as a wide variety of structurall y dissimilar 
drugs ca n inhibit Ca M . 
O ur results show that dithranol alo ne, out of the 6 dru gs tested , 
had any direct Ca M antagonist ac tivity as determined by thc 
ability o f these dru gs to inhibit CaM-dependent beef hea rt phos-
phodiestcrase activity. Dithranol has been shown in this study to 
be a potent com pctitive inhibitor of CaM at concentration s within 
the rangc likely to be enco untered in clinical usage. The m ech-
anisn; of dithranol's therapeutic actio n in psorias is has rem ained 
obscurc for m an y years. Dithrano l has been reported to inhibit 
g lu cose-6-phosphate dehydrogenase [15] and several glycolytic 
enzy mes in vitro [1 6], to redu ce mitotic activity and DNA syn-
thesis [1 7-201, and to act as an un coupler of oxidative phos-
phorylation in mitochrondria [21]. The ability to inhibit CaM 
would secm to be equ all y impo rtant and m ay also ex pl ain the 
effects of dithranol o n ON A synthesis which is known to be 
inhibited by CaM antagonists [22]. However, oxidized forms of 
dithranol are · repo rted to be less effective therapeutica lly [19,23] 
and we find fresh and oxidized forms to be equipotent in inhib-
iting CaM activity . One is led to the conclu sion that either the 
CaM antagonist ac tivi ty o f the drugs is irrelevant to their action 
in psoriasis or that oxidized forms of dithrano l should also be 
effective clini ca ll y. It has been pointed o ut th at the inherent in-
stab ility of d ithranol which leads in vitro and possibly in vivo to 
the formation of o ther derivatives m akes it diffi cult to determine 
w hich is the ac tive species in the sk in [24]. Not all of the biologic 
acti ons of dithrano l and its oxidative products ca n be accom-
modated in a consistent coherent pi cture of how dithranol acts 
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in psoriasis-for exa mple, the species of dithranol and its produc ts 
which have been found to be active against glucose-6-phosphate 
dehydrogenase [251 are different fro m those which inhibit ON A 
synthesis and induce cytotoxicity [26,27] . 
It has recently been reported that mitochondrial fun ction is the 
nlost sensiti ve target in the cell for dithranol activity (an effect 
mimicked to a lesser extent by the dithranol dimer but not b y 
dan thron), suggesting that this may be dithranol's mode of action 
clinically [28] . However, dithranol has also been reported to in-
hibit D NA repair [29] (danthron mu ch less so) and very recentl y 
a role for CaM in DNA repair has also been proposed [30] . 
Accordin gly , we would argue against prem ature discardin g of 
any new information about the biologic properties of dithranol 
and its oxidative products. 
Several dru gs whose clini cal modes of action are not full y es-
tablished have recently been found to possess CaM antagonist 
pro perties (for exa mple T amoxifen [31 D, which m ay contribute 
to their thera peutic actions. Caution must be exercised , however , 
since despite th eir CaM antagonist activity, some drugs such as 
propranolo l, in practice, exacerbate psorias is. In the case of pro-
pranolol, th e ex planation m ay be that inhibition of adenylate 
cyclase by this dru g, with a consequent fa ll in intracellular cyclic 
AMP levels, takes precedence over a weak CaM inhibition [32]. 
N o reduction in disease severity is seen among coincidentally 
psychotic psoriatic patients treated with large doses o f oral Or 
parenteral phenothiazines. Hence, it is possible that , in order to 
have an anti pso riatic effect, a sufficient .concentration of a CaM 
antagonist can be achieved safely only by topical application. 
The discovery that dithran o l, an es tablished topical treatment 
fo r psori as is, possesses CaM antagonist properties which may at 
leas t partia ll y explain its therapeutic efficacy, nevertheless pro-
vides a stimulus to investigate the use of less toxic CaM antag-
onists in the management of this disease. 
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